Chelsea Therapeutics (CHTP) Slashed 20%+ on Trade Resumption
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Outlook Therapeutics (OTLK) halted, news pending
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
Chelsea Therapeutics (CHTP) Says Northera Meets Primary Endpoint
December 4, 2012 4:07 PM ESTChelsea Therapeutics International, Ltd. (Nasdaq: CHTP) announced positive preliminary results for Study 306B, a Phase III trial evaluating the safety and efficacy of investigational drug Northera (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's Disease (PD), including achievement of the study's pre-defined,... More
Chelsea Therapeutics International (CHTP) halted, news
December 4, 2012 4:01 PM ESTChelsea Therapeutics International Ltd. (NASDAQ: CHTP) halted, news... More
